Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Calling All Blood Donors …Even Older Drugs Are Getting Steep Price Hikes, Study FindsAs Medical Marketing Soars, Is Regulation Needed?Radiation Doses From CT Scans Vary WidelyU.S. Leads Health Care Spending Among Richer Nations, But Gets LessIs Your State a Hotspot for Obesity-Linked Cancers?Health Tip: Choose the Right DoctorFDA Warns Companies on Dangerous, Unapproved Stem Cell TreatmentsMore U.S. Kids Dying From Guns, Car AccidentsRoad Rules on Smartphone Use Are Saving Bikers' Lives, TooAHA: Should Pacemakers, Defibrillators Be Recycled -- and Reused in Others?California Farm Tied to E. coli Outbreak Expands Recall Beyond Romaine LettuceHealth Tip: Use Medical Devices SafelyCalifornia Farm Implicated in Outbreak of E. coli Tied to Romaine LettuceFentanyl Now the No. 1 Opioid OD KillerHospitalizations Rising Among the HomelessElectronic Health Records Bogging Docs DownMore Are Seeking Mental Health Care, But Not Always Those Who Need It MostMillions of Americans Still Breathing Secondhand Smoke: ReportNew Approach to Opioid Crisis: Supervised Heroin Injection Programs?Many Americans Unaware of Promise of Targeted, 'Personalized' Medicine: PollAs Gun Violence Grows, U.S. Life Expectancy DropsMost Americans Lie to Their DoctorsOpioid Crisis, Suicides Driving Decline in U.S. Life Expectancy: CDCWant to Learn CPR? Try an Automated KioskHealth Surrogates Often in Dark About Loved One's WishesRestaurant 'Health Grade' Posters Could Mean Safer DiningSmoking Bans Might Help Nonsmokers' Blood PressureWarmer Winters, More Violent Crimes?Are Food Additives Good or Bad? Consumer Views VaryDrug Studies in Children Often Go Unfinished: StudyFDA Moves to Restrict Flavored E-Cig Sales, Ban Menthol CigarettesAgeism Costs Billions in Health Care DollarsAmerica Is Worried About Antibiotic ResistanceRed Cross Issues Urgent Call for Blood Ahead of the HolidaysUnder Pressure, Juul Withdraws Most Flavored E-Cigs From MarketMany Drugstores Won't Dispense Opioid Antidote as RequiredNew Cholesterol Guidelines Focus on Personalized ApproachAHA: Defibrillators Can Help Kids Survive Cardiac Arrest, TooFDA Will Ban Many Flavored E-CigarettesU.S. Smoking Rates Hit Record LowOnly a Quarter of Opioid Painkillers Taken After Most SurgeriesHome Health-Care Tests: Proceed With CautionFDA Takes on Flatulent CowsWhy Bystanders Are Less Likely to Give CPR to WomenCellphone Radiation Tied to Upped Odds for Cancer -- in RatsHealth Tip: FDA Discusses Possible Risks of Bodybuilding ProductsU.S. Hospitals Making Headway Against InfectionsAfter Mass Shootings, Blood Donations Can Go UnusedLead in Hair Dyes Must Go: FDA
Questions and AnswersLinksBook Reviews
Related Topics

Take Early Clinical Trials With a Grain of Salt

HealthDay News
by -- Robert Preidt
Updated: Feb 22nd 2018

new article illustration

THURSDAY, Feb. 22, 2018 (HealthDay News) -- More than one-third of early clinical trials exaggerate positive findings and may give patients false hope, a new study suggests.

Researchers reviewed data from 930 clinical trials published in 10 leading medical journals between early 2007 and mid-2015. The investigators found that a significant number of early trials reported effects that were 2.7 times greater than what was eventually seen in later trials.

"This phenomenon of exaggerated early results was present in a whopping 37 percent of the studies we reviewed," said study author Dr. Fares Alahdab, a research fellow with the Mayo Clinic's Evidence-Based Practice Center.

"Physicians and patients should be cautious about new or early clinical trial evidence. Exaggerated results could lead to false hope as well as possibly harmful effects," Alahdab added in a Mayo news release.

The review focused on clinical trials for drugs or devices targeting chronic conditions, including cancer, stroke, heart disease, diabetes and kidney disease.

According to Dr. M. Hassan Murad, director of Mayo's Evidence-Based Practice Center, "Often, patients are living with more than one chronic condition, and they and their doctors watch for research about new treatments. They need to be aware that the effect seen in earlier trials may not bear out over time and may be much more modest."

Murad noted that "some people may think this is an anti-innovation message."

But, he added, "To the contrary, we welcome new treatments. We just want people to know that the benefit seen in real practice, when treatments are given to people with various co-morbidities [multiple illnesses] and in different settings, may be smaller than what was seen in the earliest clinical trials."

According to the U.S. National Institutes of Health, clinical trials are key to all medical advances. They look at new ways to prevent, detect or treat disease. They can involve new drugs or new combinations of drugs, new ways of doing surgery, and new medical devices, among other topics.

The study was published online Feb. 21 in the journal Mayo Clinic Proceedings.

More information

The U.S. National Institutes of Health has more on clinical trials.